KRAS G12C occurs in ~3%–4% of CRC, translating to a sizable metastatic population with limited options and strong rationale for KRAS G12C inhibition strategies. Dual KRAS–EGFR blockade leverages ...
Efficacy and safety of serplulimab with DP induction chemotherapy followed by nimotuzumab and IMRT in locally advanced nasopharyngeal carcinoma: A retrospective study. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results